Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|January 13, 2020
Advarra Announces Advarra GPS
Advertisement
Advarra, the provider of institutional review board (IRB), institutional biosafety committee (IBC), research quality and compliance consulting services, and standards-based research technology solutions, announces Advarra GPS-a completely managed service to guide, protect, and streamline research programs for health systems, hospitals, and academic medical centers. Advarra GPS helps institutions navigate the challenges of operating a local IRB office and chart a path to increased efficiency, greater compliance, and overall scalability.
“We continue to offer our institutional partners new services to guide and improve their research programs. Advarra GPS is truly an innovation that demonstrates our commitment to supporting research institutions as they navigate an increasingly complex and challenging landscape,” said Pat Donnelly, CEO of Advarra. “Our commitment to research compliance services for institutions is unwavering. From our recent acquisition of the industry’s leading CTMS, OnCore by Forte, to the launch of Advarra GPS and many innovations to come, the future of research powered by Advarra is exciting. ”
Advarra offers the institutional reach of any independent IRB, serving well over 3,200 research institutions, health systems, and academic medical centers.
“Navigating research regulations and maintaining a local IRB office is complex and costly. Research institutions often seek increased capacity,” said James Riddle, Vice President of Institutional Services at Advarra. “Advarra GPS charts a course to success by providing a roadmap to guide these organizations through compliance risks, protect from staffing challenges, and streamline approval times.”
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
5